non sedating H1-antihistamine

DRUG2 trials

Sponsors

Sanofi

Conditions

Chronic Spontaneous UrticariaCold Urticaria

Phase 3

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

CompletedNCT04180488

SanofiChronic Spontaneous Urticaria

Start: 2019-12-11End: 2024-10-25Updated: 2025-08-20

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

CompletedNCT04681729

SanofiCold Urticaria

Start: 2020-12-10End: 2023-04-20Updated: 2025-09-10

Related Papers

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.

2026-02-18

Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naïve Patients with Chronic Spontaneous Urticaria.

2025-12-02

Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.

2025-11-22

Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels

Dermatology and Therapy2024-07-2716 citations

507 - Dupilumab demonstrates greater improvement in disease activity than standard-of-care H1-antihistamines in CSU

British Journal of Dermatology2024-02-01

Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria

SKIN The Journal of Cutaneous Medicine2024-01-16

Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria

SKIN The Journal of Cutaneous Medicine2023-11-13